libido women

It finally got approved (Sept 2023) after years of rejections from the FDA. "Studied in over 5,000 patients, Travivo (Gepirone) has been found to have a favorable safety profile and be well-tolerated. The drug's unique single mechanism of targeted 5HT1a agonism, allows for the relief of...

The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women. “Today’s approval...